Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
CRVS's Cash-to-Debt is ranked higher than
67% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CRVS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CRVS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
CRVS's Interest Coverage is ranked higher than
60% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CRVS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CRVS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 9.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -43.02
CRVS's ROE % is ranked lower than
52% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CRVS: -43.02 )
Ranked among companies with meaningful ROE % only.
CRVS' s ROE % Range Over the Past 10 Years
Min: -71.53  Med: -61.34 Max: -43.02
Current: -43.02
-71.53
-43.02
ROA % -39.42
CRVS's ROA % is ranked lower than
56% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CRVS: -39.42 )
Ranked among companies with meaningful ROA % only.
CRVS' s ROA % Range Over the Past 10 Years
Min: -56.47  Med: -47.39 Max: -30.49
Current: -39.42
-56.47
-30.49
ROC (Joel Greenblatt) % -2007.51
CRVS's ROC (Joel Greenblatt) % is ranked lower than
68% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CRVS: -2007.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2007.51  Med: -1492.68 Max: -1452.03
Current: -2007.51
-2007.51
-1452.03
GuruFocus has detected 2 Warning Signs with Corvus Pharmaceuticals Inc CRVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRVS's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

CRVS Guru Trades in Q4 2017

Jim Simons 234,200 sh (+20.54%)
Steven Cohen Sold Out
» More
Q1 2018

CRVS Guru Trades in Q1 2018

Jim Simons 426,700 sh (+82.19%)
» More
Q2 2018

CRVS Guru Trades in Q2 2018

Pioneer Investments 8,600 sh (New)
Jim Simons 324,900 sh (-23.86%)
» More
Q3 2018

CRVS Guru Trades in Q3 2018

Jim Simons 396,900 sh (+22.16%)
Pioneer Investments 8,600 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Corvus Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:XXII, NAS:NK, BOM:512529, TSE:4571, TSX:ZYME, SZSE:000004, XKRX:046210, NAS:ABUS, LSE:MPH, TSE:4564, ROCO:4128, NAS:SVRA, NAS:BSTC, NAS:MBIO, NAS:MNKD, AMEX:BTX, NAS:COOL, ROCO:6586, NAS:TORC, NAS:NLNK » details
Traded in other countries:C17.Germany,
Headquarter Location:USA
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The company is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The company is developing products that either block immune checkpoints and/or reprogram immune cells. The group competes with universities and other research institutions.

Top Ranked Articles about Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference
Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting
Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018
Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress
Corvus Pharmaceuticals to Present Data on Lead Programs at the European Society for Medical Oncology (ESMO) 2018 Congress and the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies
Corvus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

Ratios

vs
industry
vs
history
PB Ratio 1.19
CRVS's PB Ratio is ranked higher than
73% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CRVS: 1.19 )
Ranked among companies with meaningful PB Ratio only.
CRVS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.5
Current: 1.19
0
3.5
EV-to-EBIT -0.39
CRVS's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CRVS: -0.39 )
Ranked among companies with meaningful EV-to-EBIT only.
CRVS' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.98  Med: 0 Max: 0
Current: -0.39
-8.98
0
EV-to-EBITDA -0.41
CRVS's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CRVS: -0.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.14  Med: 0 Max: 0
Current: -0.41
-9.14
0
Current Ratio 16.07
CRVS's Current Ratio is ranked higher than
85% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CRVS: 16.07 )
Ranked among companies with meaningful Current Ratio only.
CRVS' s Current Ratio Range Over the Past 10 Years
Min: 10.11  Med: 16.24 Max: 111.05
Current: 16.07
10.11
111.05
Quick Ratio 16.07
CRVS's Quick Ratio is ranked higher than
85% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CRVS: 16.07 )
Ranked among companies with meaningful Quick Ratio only.
CRVS' s Quick Ratio Range Over the Past 10 Years
Min: 10.11  Med: 16.24 Max: 111.05
Current: 16.07
10.11
111.05

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.25
CRVS's Price-to-Net-Cash is ranked higher than
85% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. CRVS: 1.25 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRVS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.25  Med: 2.54 Max: 3.84
Current: 1.25
1.25
3.84
Price-to-Net-Current-Asset-Value 1.22
CRVS's Price-to-Net-Current-Asset-Value is ranked higher than
85% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. CRVS: 1.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRVS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.22  Med: 2.51 Max: 3.8
Current: 1.22
1.22
3.8
Price-to-Tangible-Book 1.20
CRVS's Price-to-Tangible-Book is ranked higher than
79% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. CRVS: 1.20 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 2.42 Max: 3.68
Current: 1.2
1.2
3.68
Earnings Yield (Greenblatt) % -253.83
CRVS's Earnings Yield (Greenblatt) % is ranked lower than
81% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CRVS: -253.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -555.6  Med: 0 Max: 0
Current: -253.83
-555.6
0

More Statistics

EPS (TTM) $ -1.97
Volatility79.44%
52-Week Range $4.87 - 13.91
Shares Outstanding (Mil)29.28

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $)
EBIT (Mil $) -55,380 -77,000 -99,500
EBITDA (Mil $) -55,250 -76,540 -98,660
EPS ($) -1.96 -2.26 -2.06
EPS without NRI ($) -1.96 -2.26 -2.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}